Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672191 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
A Phase 2 study of HIV Infections, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 12
- Study locations
NCT00672191: Completed Phase 2 study of HIV Infections, sponsored by Argos Therapeutics.
NCT00672191 is a Phase 2 study of HIV Infections that has completed, run by Argos Therapeutics. The registered enrollment target is 59 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00672191, a Phase 2 study of HIV Infections, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping anti-HIV drugs, immunotherapy can control the HIV-1 virus.
Conditions Studied
Interventions
- BIOLOGICAL AGS-004
Study Locations (12)
Ontario
- Hamilton Health Sciences - McMaster University Medical Centre - Hamilton
- The Ottawa Hospital - Ottawa
- Sunnybrook Health Sciences Center - Toronto
- Maple Leaf Clinic - Toronto
- UHN - Toronto
Quebec
- Clinique medicale l'Actuel - Montreal
- Clinique Medical du Quartier Latin - Montreal
- Montreal Chest Institute - Montreal
- CHUM - Montreal
Pennsylvania
- Practice Comprehensive Care Practice Div of Onfectious Disease & HIV Med - Philadelphia
Alberta
- Southern Alberta Clinic - Calgary
British Columbia
- Providence Health Care Society / The University of British Columbia / BC Centre for Excellence in HIV/AIDS - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT00672191 record still lists
NCT00672191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which AGS-004 is the first listed.
NCT00672191 lists 12 locations in 5 states (Ontario, Quebec, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00672191 about?
NCT00672191 is a clinical study titled "Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV". The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping a...
What is the current status of trial NCT00672191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2008-02. Estimated completion is 2011-11.
What conditions does trial NCT00672191 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00672191?
The interventions under investigation include: AGS-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00672191?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00672191 being conducted?
This trial has 12 study locations across Pennsylvania, Alberta, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00672191's enrollment target sits among peer trials
59 339th of 542 higher than 203 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia